Cargando…
FDG-PET parameters predicting mediastinal malignancy in lung cancer
BACKGROUND: Staging of mediastinal lymph nodes in non-small cell lung cancer (NSCLC) is mandatory. The maximum Standard Uptake Value (SUVmax) obtained using F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) is the best non-invasive technique available for this evaluation, but its perfor...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5146847/ https://www.ncbi.nlm.nih.gov/pubmed/27931198 http://dx.doi.org/10.1186/s12890-016-0338-6 |
_version_ | 1782473564066152448 |
---|---|
author | Serra Fortuny, M. Gallego, M. Berna, Ll Montón, C. Vigil, L. Masdeu, M. J. Fernández-Villar, A. Botana, M. I. Cordovilla, R. García-Luján, R. Cases, E. Monsó, E. |
author_facet | Serra Fortuny, M. Gallego, M. Berna, Ll Montón, C. Vigil, L. Masdeu, M. J. Fernández-Villar, A. Botana, M. I. Cordovilla, R. García-Luján, R. Cases, E. Monsó, E. |
author_sort | Serra Fortuny, M. |
collection | PubMed |
description | BACKGROUND: Staging of mediastinal lymph nodes in non-small cell lung cancer (NSCLC) is mandatory. The maximum Standard Uptake Value (SUVmax) obtained using F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) is the best non-invasive technique available for this evaluation, but its performance varies from center to center. The aim of the present study was to identify FDG-PET predictors of mediastinal malignancy that are able to minimize intercenter variability and improve the selection of subsequent staging procedures. METHOD: A multicenter study of NSCLC patients staged through FDG-PET and endobronchial ultrasonography with needle aspiration (EBUS-NA) was performed using therapeutic surgery with systematic nodal dissection as gold standard. Intercenter variability and predictive power for mediastinal malignancy of different FDG-PET measures were assessed, as well as the role of these measures for selecting additional staging procedures. RESULTS: One hundred and twenty-one NSCLC patients, of whom 94 (72%) had ≥1 hypermetabolic spots in the mediastinum, were included in the study. Mean SUVmax of the primary tumor was 12.3 (SD 6.3), and median SUVmax of the highest hypermetabolic spots in the mediastinum was 3.9 (IQR 2.4-7). Variability of FDG-PET measures between hospitals was statistically significant (p = 0.016 and p < 0.001 respectively), but lost significance when SUVmax in the mediastinum was expressed as a ratio or a subtraction from the primary tumor (SUVmax mediastinum/tumor, p = 0.083; and SUVmax mediastinum - tumor, p = 0.428 respectively). SUVmax mediastinum/tumor showed higher accuracy in the ROC analysis (AUC 0.77 CI 0.68-0.85, p < 0.001), and showed predictive power for mediastinal malignancy when using a 0.4 cutoff (OR 6.62, 95%CI 2.98-14.69). Sensitivities and negative predictive values of clinical staging through EBUS-NA attained values ranging between 57% and 92% after FDG-PET, which improved with additional techniques when the tumor had a diameter >3 cm and/or a SUVmax mediastinum/tumor ratio >0.4. CONCLUSION: The SUVmax mediastinum/tumor ratio is a good predictor of regional tumor extension in NSCLC. This measure is not influenced by intercenter variability and has an accuracy of over 70% for the identification of malignancy when using a 0.4 cutoff. |
format | Online Article Text |
id | pubmed-5146847 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-51468472016-12-15 FDG-PET parameters predicting mediastinal malignancy in lung cancer Serra Fortuny, M. Gallego, M. Berna, Ll Montón, C. Vigil, L. Masdeu, M. J. Fernández-Villar, A. Botana, M. I. Cordovilla, R. García-Luján, R. Cases, E. Monsó, E. BMC Pulm Med Research Article BACKGROUND: Staging of mediastinal lymph nodes in non-small cell lung cancer (NSCLC) is mandatory. The maximum Standard Uptake Value (SUVmax) obtained using F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) is the best non-invasive technique available for this evaluation, but its performance varies from center to center. The aim of the present study was to identify FDG-PET predictors of mediastinal malignancy that are able to minimize intercenter variability and improve the selection of subsequent staging procedures. METHOD: A multicenter study of NSCLC patients staged through FDG-PET and endobronchial ultrasonography with needle aspiration (EBUS-NA) was performed using therapeutic surgery with systematic nodal dissection as gold standard. Intercenter variability and predictive power for mediastinal malignancy of different FDG-PET measures were assessed, as well as the role of these measures for selecting additional staging procedures. RESULTS: One hundred and twenty-one NSCLC patients, of whom 94 (72%) had ≥1 hypermetabolic spots in the mediastinum, were included in the study. Mean SUVmax of the primary tumor was 12.3 (SD 6.3), and median SUVmax of the highest hypermetabolic spots in the mediastinum was 3.9 (IQR 2.4-7). Variability of FDG-PET measures between hospitals was statistically significant (p = 0.016 and p < 0.001 respectively), but lost significance when SUVmax in the mediastinum was expressed as a ratio or a subtraction from the primary tumor (SUVmax mediastinum/tumor, p = 0.083; and SUVmax mediastinum - tumor, p = 0.428 respectively). SUVmax mediastinum/tumor showed higher accuracy in the ROC analysis (AUC 0.77 CI 0.68-0.85, p < 0.001), and showed predictive power for mediastinal malignancy when using a 0.4 cutoff (OR 6.62, 95%CI 2.98-14.69). Sensitivities and negative predictive values of clinical staging through EBUS-NA attained values ranging between 57% and 92% after FDG-PET, which improved with additional techniques when the tumor had a diameter >3 cm and/or a SUVmax mediastinum/tumor ratio >0.4. CONCLUSION: The SUVmax mediastinum/tumor ratio is a good predictor of regional tumor extension in NSCLC. This measure is not influenced by intercenter variability and has an accuracy of over 70% for the identification of malignancy when using a 0.4 cutoff. BioMed Central 2016-12-08 /pmc/articles/PMC5146847/ /pubmed/27931198 http://dx.doi.org/10.1186/s12890-016-0338-6 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Serra Fortuny, M. Gallego, M. Berna, Ll Montón, C. Vigil, L. Masdeu, M. J. Fernández-Villar, A. Botana, M. I. Cordovilla, R. García-Luján, R. Cases, E. Monsó, E. FDG-PET parameters predicting mediastinal malignancy in lung cancer |
title | FDG-PET parameters predicting mediastinal malignancy in lung cancer |
title_full | FDG-PET parameters predicting mediastinal malignancy in lung cancer |
title_fullStr | FDG-PET parameters predicting mediastinal malignancy in lung cancer |
title_full_unstemmed | FDG-PET parameters predicting mediastinal malignancy in lung cancer |
title_short | FDG-PET parameters predicting mediastinal malignancy in lung cancer |
title_sort | fdg-pet parameters predicting mediastinal malignancy in lung cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5146847/ https://www.ncbi.nlm.nih.gov/pubmed/27931198 http://dx.doi.org/10.1186/s12890-016-0338-6 |
work_keys_str_mv | AT serrafortunym fdgpetparameterspredictingmediastinalmalignancyinlungcancer AT gallegom fdgpetparameterspredictingmediastinalmalignancyinlungcancer AT bernall fdgpetparameterspredictingmediastinalmalignancyinlungcancer AT montonc fdgpetparameterspredictingmediastinalmalignancyinlungcancer AT vigill fdgpetparameterspredictingmediastinalmalignancyinlungcancer AT masdeumj fdgpetparameterspredictingmediastinalmalignancyinlungcancer AT fernandezvillara fdgpetparameterspredictingmediastinalmalignancyinlungcancer AT botanami fdgpetparameterspredictingmediastinalmalignancyinlungcancer AT cordovillar fdgpetparameterspredictingmediastinalmalignancyinlungcancer AT garcialujanr fdgpetparameterspredictingmediastinalmalignancyinlungcancer AT casese fdgpetparameterspredictingmediastinalmalignancyinlungcancer AT monsoe fdgpetparameterspredictingmediastinalmalignancyinlungcancer |